{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:56:01Z","timestamp":1791276961623,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eris Lifesciences Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on heart failure (HF) phenotypes in India remain limited. We examined clinical characteristics and factors associated with HF phenotype defined according to ejection fraction (EF) in a large multicentre outpatient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cross-sectional analysis of adult HF outpatients with documented EF at centres across India (April 2021\u2013March 2023). Patients were classified as HFrEF (EF \u226440%), HFmrEF (41%\u201349%), or HFpEF (\u226550%); multivariable logistic regression identified factors associated with phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1207 patients (62 \u00b1 10 years; 73% male), HFrEF was present in 822 (68.1%), HFmrEF in 89 (7.4%), and HFpEF in 296 (24.5%). Patients with HFpEF had higher systolic blood pressure (153 \u00b1 26 vs 122 \u00b1 25\u2005mmHg), higher body mass index (BMI; 27.5 \u00b1 4.9 vs 26.4 \u00b1 4.4\u2005kg\/m2), and more chronic kidney disease (45% vs 23%) and stroke (27% vs 6.2%) than those with HFrEF (all P \u2264 .003). Ischaemic heart disease (66% vs 56%; P = .002) and higher NT-proBNP [median 3705 (481\u20136232) vs 140 (121\u2013521) pg\/ml; P &amp;lt; .001) were more common in HFrEF. In multivariable analysis, higher BMI [odds ratio (OR) 1.35 per 5\u2005kg\/m2, 95% confidence interval (CI) 1.10\u20131.65], higher systolic blood pressure (OR 1.48 per 10\u2005mmHg, 95% CI 1.37\u20131.60), and stroke (OR 1.99, 95% CI 1.11\u20133.54) were associated with higher odds of HFpEF, whereas higher NT-proBNP (OR 0.46, 95% CI 0.40\u20130.53) and diabetes (OR 0.56, 95% CI 0.38\u20130.83) were associated with lower odds of HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher BMI and blood pressure were associated with HFpEF, whereas elevated NT-proBNP and diabetes were associated with HFrEF. These cross-sectional associations may support phenotype-specific management of HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag236","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:50:21Z","timestamp":1788954621000},"source":"Crossref","is-referenced-by-count":0,"title":["Demographics and clinical characteristics of Indian patients with heart failure visiting outpatient clinics: a cross-sectional observational study"],"prefix":"10.1093","volume":"13","author":[{"given":"Kamal","family":"Sharma","sequence":"first","affiliation":[{"name":"SAL Hospital , Ahmedabad, Gujarat ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Mohan","sequence":"additional","affiliation":[{"name":"Institute of Heart & Vascular Diseases, Jaipur Golden Hospital , Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-9274","authenticated-orcid":false,"given":"Shantanu","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Sengupta Hospital and Research Institute , Nagpur ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumitra","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Manipal Hospitals , Kolkata, West Bengal ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Mullasari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Madras Medical Mission , Chennai ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Christopher","sequence":"additional","affiliation":[{"name":"Department of Cardiac Imaging, CARE Hospitals , Hyderabad ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P B","family":"Jayagopal","sequence":"additional","affiliation":[{"name":"Lakshmi Hospital , Palakkad, Kerala ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Medical Affairs, Eris Lifesciences Limited , Ahmedabad, Gujarat ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-0488","authenticated-orcid":false,"given":"Willem J","family":"Verberk","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University , Maastricht ,","place":["The Netherlands"]},{"name":"Mexlid, Research in Life Sciences and Medical Devices , Gennep ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026100604475361600_xvag236-B1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026100604475361600_xvag236-B2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1751-7141.2011.01011","article-title":"Heart failure: epidemiology and prevention in India","volume":"23","author":"Huffman","year":"2010","journal-title":"Natl Med J India"},{"key":"2026100604475361600_xvag236-B3","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1002\/ehf2.14096","article-title":"Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry","volume":"9","author":"Harikrishnan","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026100604475361600_xvag236-B4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026100604475361600_xvag236-B5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002477","article-title":"Clinical phenotypes in heart failure with preserved ejection fraction","volume":"5","author":"Samson","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026100604475361600_xvag236-B6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026100604475361600_xvag236-B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5070062","article-title":"Heart failure: diagnosis, management and utilization","volume":"5","author":"Inamdar","year":"2016","journal-title":"J Clin Med"},{"key":"2026100604475361600_xvag236-B8","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"Lancet"},{"key":"2026100604475361600_xvag236-B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061642","article-title":"Clinical, laboratory and lung ultrasound assessment of congestion in patients with acute heart failure","volume":"11","author":"Palazzuoli","year":"2022","journal-title":"J Clin Med"},{"key":"2026100604475361600_xvag236-B10","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA clinical practice guideline on heart failure","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026100604475361600_xvag236-B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"26","author":"Authors\/Task Force Members","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026100604475361600_xvag236-B12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa042330","article-title":"N-Terminal Pro\u2013B-Type natriuretic peptide and long-term mortality in stable coronary heart disease","volume":"352","author":"Kragelund","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B13","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.110.954388","article-title":"Diastolic and systolic heart failure are distinct phenotypes of the heart failure syndrome","volume":"123","author":"Borlaug","year":"2011","journal-title":"Circulation"},{"key":"2026100604475361600_xvag236-B14","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2021-319605","article-title":"Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management","volume":"108","author":"Gevaert","year":"2022","journal-title":"Heart"},{"key":"2026100604475361600_xvag236-B15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.hlc.2021.09.019","article-title":"Characteristics and clinical outcomes in patients with heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: insights from the VCOR heart failure snapshot","volume":"31","author":"Tan","year":"2022","journal-title":"Heart Lung Circ"},{"key":"2026100604475361600_xvag236-B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026100604475361600_xvag236-B17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ejhf.283","article-title":"Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum heart failure registry","volume":"17","author":"Harikrishnan","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026100604475361600_xvag236-B18","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"JACC"},{"key":"2026100604475361600_xvag236-B19","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ejhf.3445","article-title":"Heart failure in Europe: guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction\u2014the ESC EORP heart failure III registry","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026100604475361600_xvag236-B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s43044-021-00161-w","article-title":"Clinical characteristics and outcomes of patients admitted with acute heart failure: insights from a single-center heart failure registry in South India","volume":"73","author":"Shukkoor","year":"2021","journal-title":"Egypt Heart J"},{"key":"2026100604475361600_xvag236-B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026100604475361600_xvag236-B22","doi-asserted-by":"publisher","first-page":"102491","DOI":"10.1016\/j.jchf.2025.03.037","article-title":"Etiology of heart failure across the ejection fraction Spectrum and association with prognosis","volume":"13","author":"Kozman","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026100604475361600_xvag236-B23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes Mellitus and HFrEF: the CHAMP-HF registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026100604475361600_xvag236-B24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF diabetes atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100604475361600_xvag236-B25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"2026100604475361600_xvag236-B26","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.amjmed.2017.04.010","article-title":"Diabetes Mellitus and heart failure","volume":"130","author":"Lehrke","year":"2017","journal-title":"Am J Med"},{"key":"2026100604475361600_xvag236-B27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cardfail.2024.10.440","article-title":"Prognostic utility and cutoff differences in NT-proBNP levels across subgroups in heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF registry","volume":"31","author":"Sakamoto","year":"2025","journal-title":"J Card Fail"},{"key":"2026100604475361600_xvag236-B28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ahj.2017.12.021","article-title":"Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril\/valsartan therapy for heart failure (PROVE-HF)","volume":"199","author":"Januzzi","year":"2018","journal-title":"Am Heart J"},{"key":"2026100604475361600_xvag236-B29","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.jacc.2022.02.013","article-title":"Sex-based differences in heart failure","volume":"79","author":"Khan","year":"2022","journal-title":"JACC"},{"key":"2026100604475361600_xvag236-B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CEOR.S576426","article-title":"Trends in healthcare costs in heart failure and its clinical phenotypes during the implementation of SGLT2 inhibitors: a Finnish registry study","volume":"18","author":"Hansen","year":"2026","journal-title":"Clinicoecon Outcomes Res"},{"key":"2026100604475361600_xvag236-B31","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026100604475361600_xvag236-B32","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B33","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2026100604475361600_xvag236-B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2026.03.021","article-title":"Practical Guideline-Directed Medical Therapy (PGDMT) in heart failure with reduced and mildly reduced ejection fraction\u2014real world multicenter cross-sectional interim analysis at enrollment: data from Associates for Cardiology Education and Research Chronic Heart Failure (ACERT CHEF) registry","author":"Dorairaj","year":"2026","journal-title":"J Card Fail"},{"key":"2026100604475361600_xvag236-B35","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B37","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B38","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B40","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026100604475361600_xvag236-B41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100604475361600_xvag236-B42","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag236\/71017620\/xvag236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag236\/71017620\/xvag236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag236\/71017620\/xvag236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:57Z","timestamp":1791276477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag236\/8789823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag236","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,27]]},"article-number":"xvag236"}}